Stocks Health care LCTX
NYSE · Health careLineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. brought in $13.1M of revenue over the twelve months to June 30, 2026, up 19.9% from a year earlier. It posted a net loss of $32.3M. In fiscal 2025 capital spending exceeded operating cash flow by $19.4M. At June 30, 2026 it held $37.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Lineage Cell Therapeutics, Inc. does
Lineage Cell Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker LCTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $14.6M | -$63.5M | -$0.28 | -$19.4M |
| 2024 | $9.5M | -$18.6M | -$0.09 | -$23.7M |
| 2023 | $8.9M | -$21.5M | -$0.12 | -$29.2M |
| 2022 | $14.7M | -$26.3M | -$0.15 | $646K |
| 2021 | $4.3M | -$43M | -$0.26 | -$23.9M |
| 2020 | $1.8M | -$20.6M | -$0.14 | -$19.8M |
Latest SEC filings
What Lineage Cell Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 12, 2026
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
- May 12, 2026
- April 29, 2026
- April 29, 2026Additional proxy material DEFA14A
- April 29, 2026Proxy statement DEF 14A
- March 11, 2026
Questions about LCTX
What does Lineage Cell Therapeutics, Inc. do?
Lineage Cell Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NYSE under the ticker LCTX.
Is Lineage Cell Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $32.3M on revenue of $13.1M.
How much revenue does Lineage Cell Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Lineage Cell Therapeutics, Inc. reported revenue of $13.1M. That is 19.9% more than a year earlier.
When did Lineage Cell Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026.
Similar companies
Follow LCTX
Get an email when Lineage Cell Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow LCTX: get an email when it filesWhere the numbers come from
Financial figures are the values Lineage Cell Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.